Understanding the gender disparity in bladder cancer risk: The impact of sex hormones and liver on bladder susceptibility to carcinogens

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 31, Issue 4, 2013, Pages 287-304

  Zhang, Yuesheng ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Androgen; Aromatic amines; Bladder carcinogenesis; Carcinogen metabolism; Estrogen

Indexed keywords

AFTER-TREATMENT; ANDROGEN; AROMATIC AMINES; BLADDER CANCERS; BLADDER CARCINOGENESIS; ESTROGEN; GENDER DISPARITY; METABOLIC ENZYMES;

AMINES; ANIMALS; DIGITAL STORAGE; ENZYMES; HORMONES; METABOLISM; PATHOLOGY;

CARCINOGENS;

2 FLUORENYLAMINE; ANDROGEN; AROMATIC AMINE; CARCINOGEN; DRINKING WATER; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GLUCURONOSYLTRANSFERASE; GLYCINE DERIVATIVE; LIVER ENZYME; MESSENGER RNA; N (2 FLUORENYL)ACETAMIDE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; SEX HORMONE; TOBACCO SMOKE;

ACETYLATION; ARTICLE; BIOTRANSFORMATION; BLADDER CARCINOGENESIS; CANCER RISK; CARCINOGENICITY; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; ENZYME SPECIFICITY; GLUCURONIDATION; HUMAN; HYDROXYLATION; LIVER CARCINOGENESIS; LIVER FUNCTION; LIVER MICROSOME; LIVER TOXICITY; METABOLIC ACTIVATION; NONHUMAN; SEX DIFFERENCE; SULFATION; URINARY EXCRETION;

ANIMALS; BIOTRANSFORMATION; CARCINOGENS, ENVIRONMENTAL; FEMALE; GONADAL STEROID HORMONES; HUMANS; LIVER; MALE; MICE; RATS; RISK FACTORS; SEX FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84888367154     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2013.844755     Document Type: Article

References (96)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-1330.
3. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;18:1174-1182.
4. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737-745.
5. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF Jr. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82:1636-1640.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
7. Vineis P. Epidemiology of cancer from exposure to arylamines. Environ Health Perspect. 1994;102Suppl 6:7-10.
8. Riedel K, Scherer G, Engl J, Hagedorn HW, Tricker AR. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol. 2006;30:187-195.
9. Talaska G. Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2003;21:29-43.
10. Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:503-507.
11. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011;20:1629-1637.
12. Guo H-R, Tseng Y-C. Arsenic in drinking water and bladder cancer: comparison between studies based on cancer registry and death certificates. Environmental Geochemistry and Health. 2000;22:83-91.
13. Shen J, Wanibuchi H, Waalkes MP, Salim EI, Kinoshita A, Yoshida K, Endo G, Fukushima S. A comparative study of the sub-chronic toxic effects of three organic arsenical compounds on the urothelium in F344 rats; gender-based differences in response. Toxicol Appl Pharmacol. 2006;210:171-180.
14. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992;97:259-267.
15. Smith CJ, Perfetti TA, Garg R, Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem Toxicol. 2003;41:807-817.
16. Stabbert R, Schafer KH, Biefel C, Rustemeier K. Analysis of aromatic amines in cigarette smoke. Rapid Commun Mass Spectrom. 2003;17:2125-2132.
17. Talaska G, al-Juburi AZ, Kadlubar FF. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci U S A. 1991;88:5350-5354.
18. Talaska G, Schamer M, Skipper P, Tannenbaum S, Caporaso N, Unruh L, Kadlubar FF, Bartsch H, Malaveille C, Vineis P. Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol Biomarkers Prev. 1991;1:61-66.
19. Schieferstein GJ, Littlefield NA, Gaylor DW, Sheldon WG, Burger GT. Carcinogenesis of 4-aminobiphenyl in BALB/cStCrlfC3Hf/Nctr mice. Eur J Cancer Clin Oncol. 1985;21:865-873.
20. Beland FA, Beranek DT, Dooley KL, Heflich RH, Kadlubar FF. Arylamine-DNA adducts in vitro and in vivo: their role in bacterial mutagenesis and urinary bladder carcinogenesis. Environ Health Perspect. 1983;49:125-134.
21. Poirier MC, Beland FA. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in rodents. Environ Health Perspect. 1994;102Suppl 6:161-165.
22. Al-Zoughool M, Succop P, Desai P, Vietas J, Talaska G. Effects of Nglucuronidation on urinary bladder genotoxicity of 4-aminobiphenyl in male and female mice. Environmental Toxicology and Pharmacology. 2006;22:153-159.
23. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, Nebert DW. 4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J Natl Cancer Inst. 2003;95:1227-1237.
24. Flammang TJ, Couch LH, Levy GN, Weber WW, Wise CK. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl. Carcinogenesis. 1992;13:1887-1891.
25. Clayson DB, Lawson TA, Pringle JA. The carcinogenic action of 2-aminodiphenylene oxide and 4-aminodiphenyl on the bladder and liver of the C57 X IF mouse. Br J Cancer. 1967;21:755-762.
26. Sugamori KS, Brenneman D, Sanchez O, Doll MA, Hein DW, PierceWM Jr, Grant DM. Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. Cancer Lett. 2012;318:206-213.
27. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, Gonzalez FJ. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis. 1999;20:1825-1830.
28. Maeura Y, Weisburger JH, Williams GM. Dose-dependent reduction of N-2-fluorenylacetamide-induced liver cancer and enhancement of bladder cancer in rats by butylated hydroxytoluene. Cancer Res. 1984;44:1604-1610.
29. Williams GM, Tanaka T, Maruyama H, Maeura Y, Weisburger JH, Zang E. Modulation by butylated hydroxytoluene of liver and bladder carcinogenesis induced by chronic low-level exposure to 2-acetylaminofluorene. Cancer Res. 1991;51:6224-6230.
30. Grantham PH, Weisburger JH, Weisburger EK. Effect of the antioxidant butylated hydroxytoluene (BHT) on the metabolism of the carcinogens N-2-fluorenylacetamide and N-hydroxy-N-2-fluorenylacetamide. Food Cosmet Toxicol. 1973;11:209-217.
31. Cha YN, Heine HS. Comparative effects of dietary administration of 2(3)-tertbutyl-4-hydroxyanisole and 3,5-di-tert-butyl-4-hydroxytoluene on several hepatic enzyme activities in mice and rats. Cancer Res. 1982;42:2609-2615.
32. Radomski JL, Brill E. The role of N-oxidation products of aromatic amines in the induction of bladder cancer in the dog. Arch Toxikol. 1971;28:159-175.
33. McMahon RE, Turner JC, Whitaker GW. The N-hydroxylation and ringhydroxylation of 4-aminobiphenyl in vitro by hepatic mono-oxygenases from rat, mouse, hamster, rabbit and guinea-pig. Xenobiotica. 1980;10:469-481.
34. Weisburger EK, Grantham PH, Weisburger JH. Differences in the metabolism of N-hydroxy-N-2-fluorenylacetamide in male and female rats. Biochemistry. 1964;3:808-812.
35. Hammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar FF. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis. 1997;18:851-854.
36. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, Yokoi T. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer. 2006;119:2520-2526.
37. Imaoka S, Yoneda Y, Sugimoto T, Ikemoto S, Hiroi T, Yamamoto K, Nakatani T, Funae Y. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett. 2001;166:119-123.
38. Kirlin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK, Hein DW. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferasemediated activation of N-hydroxyarylamines by human bladder cytosol. Cancer Res. 1989;49:2448-2454.
39. Miller EC. Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. Cancer Res. 1978;38:1479-1496.
40. Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochem Pharmacol. 1996;51:1679-1685.
41. Ciotti M, Lakshmi VM, Basu N, Davis BB, Owens IS, Zenser TV. Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP glucuronosyl transferases and pH stability of glucuronides. Carcinogenesis. 1999;20: 1963-1969.
42. Ramaswamy SG, Jakoby WB. Amine N-sulfotransferase. J Biol Chem. 1987;262:10039-10043.
43. Gilissen RA, Hume R, Meerman JH, Coughtrie MW. Sulphation of N-hydroxy-4-aminobiphenyl and N-hydroxy-4-acetylaminobiphenyl by human foetal and neonatal sulphotransferase. Biochem Pharmacol. 1994;48:837-840.
44. Gilissen RA, Ringer DP, Stavenuiter HJ, Mulder GJ, Meerman JH. Sulfation of hydroxylamines and hydroxamic acids in liver cytosol from male and female rats and purified aryl sulfotransferase IV. Carcinogenesis. 1992;13:1699-1703.
45. Sim E, Hickman D, Coroneos E, Kelly SL. Arylamine N-acetyltransferase. Biochem Soc Trans. 1992;20:304-309.
46. Bartsch H, Dworkin M, Miller JA, Miller EC. Electrophilic N-acetoxyaminoarenes derived from carcinogenic N-hydroxy-N-acetylaminoarenes by enzymatic deacetylation and transacetylation in liver. Biochim Biophys Acta. 1972;286: 272-298.
47. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000;10:115-122.
48. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev. 2000;9:461-467.
49. Sugamori KS, Brenneman D, Grant DM. In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. Drug Metab Dispos. 2006;34:1697-1702.
50. Radomski JL, Hearn WL, Radomski T, Moreno H, Scott WE. Isolation of the glucuronic acid conjugate of n-hydroxy-4-aminobiphenyl from dog urine and its mutagenic activity. Cancer Res. 1977;37:1757-1762.
51. Babu SR, Lakshmi VM, Hsu FF, Zenser TV, Davis BB. Glucuronidation of Nhydroxy metabolites of N-acetylbenzidine. Carcinogenesis. 1995;16:3069-3074.
52. Rothman N, Talaska G, Hayes RB, Bhatnagar VK, Bell DA, Lakshmi VM, et al. Acidic urine pH is associated with elevated levels of free urinary benzidine and Nacetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiol Biomarkers Prev. 1997;6:1039-1042.
53. Fripp PJ. The origin of urinary beta-glucuronidase. Br J Cancer. 1965;19:330-335.
54. Zenser TV, Lakshmi VM, Davis BB. Human and Escherichia coli betaglucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos. 1999;27:1064-1067.
55. Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 1977;37:805-814.
56. Paigen K, Peterson J, Paigen B. Role of urinary beta-glucuronidase in human bladder cancer. Cancer Res. 1984;44:3620-3623.
57. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyl transferases. Curr Drug Metab. 2000;1:143-161.
58. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005;15:677-685.
59. Zenser TV, Lakshmi VM, Hsu FF, Davis BB. Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res. 2002;506-507:29-40.
60. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP glucuronosyl transferase 1A3. Drug Metab Dispos. 1998;26:507-512.
61. Mackenzie PI, Rodbourn L, Iyanagi T. Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases. Cancer Res. 1993;53:1529-1533.
62. Buckley DB, Klaassen CD. Tissue-and gender-specific mRNA expression of UDP glucuronosyl transferases (UGTs) in mice. Drug Metab Dispos. 2007;35:121-127.
63. Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog. 2013;52:94-102.
64. Yasuda S, Idell S, Fu J, Carter G, Snow R, Liu MC. Cigarette smoke toxicants as substrates and inhibitors for human cytosolic SULTs. Toxicol Appl Pharmacol. 2007;221:13-20.
65. DeBaun JR, Miller EC, Miller JA. N-hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein-(methion-S-yl) binding in rat liver. Cancer Res. 1970;30:577-595.
66. Weisburger JH, Yamamoto RS, Williams GM, Grantham PH, Matsushima T, Weisburger EK. On the sulfate ester of N-hydroxy-N-2-fluorenylacetamide as a key ultimate hepatocarcinogen in the rat. Cancer Res. 1972;32:491-500.
67. DeBaun JR, Smith JY, Miller EC, Miller JA. Reactivity in vivo of the carcinogen N-hydroxy-2-acetylaminofluorene: increase by sulfate ion. Science. 1970;167:184-186.
68. Chou HC, Lang NP, Kadlubar FF. Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis. 1995;16:413-417.
69. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB. Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica. 1988;18:849-856.
70. Reuber MD. Influence of age and sex on carcinoma and cirrhosis of the liver in AXC strain rats ingesting 0.025% N-2-fluorenyldiacetamide. Pathol Microbiol (Basel). 1975;43:31-37.
71. Alnouti Y, Klaassen CD. Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Toxicol Sci. 2006;93:242-255.
72. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27:187-196.
73. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res. 1975;3:73-79.
74. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8:587-594.
75. Suzuki E, Aoki J, Okada M. Metabolic fate of N-butyl-N-(4-hydroxybutyl) nitrosamine and N, N-dibutylnitrosamine in the guinea pig, with reference to their carcinogenic effects on the urinary bladder. Gann. 1981;72:547-551.
76. Okada M, Ishidate M. Metabolic fate of N-n-butyl-N-(4-hydroxybutyl)- nitrosamine and its analogues. Selective induction of urinary bladder tumours in the rat. Xenobiotica. 1977;7:11-24.
77. Airoldi L, Bonfanti M, Magagnotti C, Fanelli R. Development of an experimental model for studying bladder carcinogen metabolism using the isolated rat urinary bladder. Cancer Res. 1987;47:3697-3700.
78. Suzuki E, Mochizuki M, Okada M. Relationship of urinary N-butyl-N-(3-carboxypropyl)nitrosamine to susceptibility of animals to bladder carcinogenesis by Nbutyl-N-(4-hydroxybutyl)nitrosamine. Gann. 1983;74:360-364.
79. Suzuki E, Okada M. Metabolic fate of N-butyl-N-(4-hydroxybutyl) nitrosamine in the rat. Gann. 1980;71:856-862.
80. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and Nnitrosobutyl (3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis. 1990;11:1437-1440.
81. Suzuki E, Anjo T, Aoki J, Okada M. Species variations in the metabolism of Nbutyl-N-(4-hydroxybutyl) nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Gann. 1983;74:60-68.
82. Nagao M, Suzuki E, Yasuo K, Yahagi T, Seino Y. Mutagenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine, a bladder carcinogen, and related compounds. Cancer Res. 1977;37:399-407.
83. Hashimoto Y, Suzuki E, Okada M. Induction of urinary bladder tumors in ACIN rats by butyl(3-carboxypropyl)nitrosoamine, a major urinary metabolite of butyl-(4-hydroxybutyl)nitrosoamine. Gann. 1972;63:637-638.
84. Hirose M, Fukushima S, Hananouchi M, Shirai T, Ogiso T. Different susceptibilities of the urinary bladder epithelium of animal species to three nitroso compounds. Gann. 1976;67:175-189.
85. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558-568.
86. Shirai T, Tsuda H, Ogiso T, Hirose M, Ito N. Organ specific modifying potential of ethinyl estradiol on carcinogenesis initiated with different carcinogens. Carcinogenesis. 1987;8:115-119.
87. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997;31:360-364.
88. Pelletier G. Localization of androgen and estrogen receptors in rat and primate tissues. Histol Histopathol. 2000;15:1261-1270.
89. Makela S, Strauss L, Kuiper G, Valve E, Salmi S, Santti R, Gustafsson JA. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol. 2000;170:219-229.
90. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol. 2006;163:236-244.
91. Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, et al. Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev. 2011;20:1156-1170.
92. Cantwell MM, Lacey JV Jr, Schairer C, Schatzkin A, Michaud DS. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer. 2006;119:2398-2401.
93. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007;28:1343-1354.
94. Ding Y, Paonessa JD, Randall KL, Argoti D, Chen L, Vouros P, Zhang Y. Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. Carcinogenesis. 2010;31:1999-2003.
95. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91:605-613.
96. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, McCann SE. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:938-944.